Sodium Stibogluconate (SSG)
Treatment for Visceral Leishmaniasis
Typical Dosage: 20 mg/kg/day intravenously or intramuscularly for 28 days
Effectiveness
88%
Safety Score
45%
Clinical Trials
5
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
20 mg/kg/day intravenously or intramuscularly for 28 days
Time to Effect
3-4 weeks
Treatment Duration
28 days
Evidence Quality
MODERATENumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$6,000
Side Effect Mgmt:$2,000
Total Annual:$9,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$10,227
Cost per Remission
$10,588
Comparison vs Liposomal Amphotericin B
Cost Difference
$-9,000/year
Less expensive
QALY Difference
-0.40 QALYs
Worse outcomes
Dominance
No dominance
Sodium Stibogluconate (SSG) Outcomes
for Visceral Leishmaniasis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+88%
Remission Rate
+85%
Common Side Effects
Cardiotoxicity (ECG changes, QT prolongation)
+30%
Pancreatitis (elevated amylase/lipase)
+20%
Arthralgia/Myalgia
+25%
Hepatotoxicity (elevated liver enzymes)
+10%
Nephrotoxicity
+5%
Sources:
Active Clinical Trials
1 active trial recruiting for Sodium Stibogluconate (SSG) in Visceral Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
NCT04342715ACTIVE NOT RECRUITING
216 participants
OBSERVATIONAL
Nairobi, Kenya
Started: May 22, 2022
Completed Clinical Trials
4 completed trials for Sodium Stibogluconate (SSG) in Visceral Leishmaniasis
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
NCT00255567COMPLETEDPHASE3
1.14K participants
INTERVENTIONAL
Arba Minch, Ethiopia +4 more
Started: Nov 1, 2004
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
NCT03129646COMPLETEDPHASE3
439 participants
INTERVENTIONAL
Ābderafī, Ethiopia +6 more
Started: Jan 24, 2018
Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
NCT01067443COMPLETEDPHASE2
151 participants
INTERVENTIONAL
Kimalel, Kenya +2 more
Started: Mar 1, 2010
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
NCT05957978COMPLETEDPHASE2
52 participants
INTERVENTIONAL
Gonder, Ethiopia
Started: Mar 29, 2024